Related Experiment Video

Updated: May 15, 2026

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy

Zherui Wu1, Daniel Martinez-Fong, Jean Trédaniel

  • 1INSERM-UPMC UMR_S938, Hôpital Saint-Antoine Paris, France.

Frontiers in Endocrinology
|January 22, 2013
PubMed

Insights

The neurotensinergic system promotes cancer progression in multiple cancer types. Targeting this system offers a promising strategy for developing novel, personalized cancer therapies with improved efficacy and reduced side effects.

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Research
  • Therapeutic Target Discovery

Background:

  • Cancer remains a significant global health challenge.
  • Personalized medicine, driven by targeted therapies, represents a future direction in cancer treatment.
  • The neurotensinergic system is implicated in the progression of various cancers, including pancreatic, prostate, lung, breast, and colon cancer.

Purpose of the Study:

  • To review the role of the neurotensinergic system in cancer progression.
  • To explore the regulation and mechanisms of the neurotensinergic system.
  • To highlight its potential as a therapeutic target for cancer treatment.

Main Methods:

  • Literature review of studies investigating the neurotensinergic system in cancer.
  • Analysis of oncogenic signaling pathways regulated by the neurotensinergic system (e.g., PKC/ERK, AKT).
  • Evaluation of evidence supporting the neurotensinergic system as a therapeutic target.

Main Results:

  • The neurotensinergic system enhances cancer progression across diverse cancer types.
  • This system activates key oncogenic signaling pathways crucial for tumor growth and survival.
  • Evidence suggests the neurotensinergic system's involvement in multiple cancers, indicating broad therapeutic potential.

Conclusions:

  • The neurotensinergic system plays a significant role in promoting cancer progression.
  • Targeting the neurotensinergic system presents a viable strategy for developing novel cancer therapies.
  • Further research into the neurotensinergic system could lead to effective personalized treatments for various cancers.
Keywords:
cancer progressioncancer therapycarcinogenesisneurotensinneurotensin receptor

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...